SCHEMBL708873

SCHEMBL708873

O=C1CCC2(CCCCC2)C1

nearest known ligand 0.36

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 2/20 0.36
TRIM33 Q9UPN9 2/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13084100 1.00 TRIM24 (0.36) TRIM24TRIM33ALDH1A1
SCHEMBL14441602 0.97 TRIM24 (0.33) TRIM24TRIM33ALDH1A1
SCHEMBL13563888 0.92
SCHEMBL3241777 0.90 TRIM24 (0.43) TRIM24TRIM33ALDH1A1
SCHEMBL2775918 0.86 TRIM24 (0.40) TRIM24TRIM33ALDH1A1
SCHEMBL25225227 0.86
SCHEMBL515401 0.83 TRIM24 (0.47) TRIM24TRIM33ALDH1A1
SCHEMBL515266 0.83 TRIM24 (0.47) TRIM24TRIM33ALDH1A1
SCHEMBL5740964 0.81 TRIM24 (0.40) TRIM24TRIM33ALDH1A1
SCHEMBL1700931 0.81

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210380606-A1 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2021-12-09 US claimed
EP-2983473-A2 PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF ALS Mountain Llc (US) 2016-02-17 EP claimed
WO-2014144130-A2 PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF ALS MOUNTAIN LLC (US) 2014-09-18 WO claimed
EP-1461339-A2 SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS Acadia Pharmaceuticals Inc. (US) 2004-09-29 EP claimed
WO-2003057698-A2 SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS ACADIA PHARMACEUTICALS, INC. (US) 2003-07-17 WO claimed
EP-0743312-B1 Spiroheterocyclic compounds, process for their preparation and pharmaceutical compositions containing them ADIR (FR) 1999-11-17 EP claimed
EP-0743312-A1 Spiroheterocyclic compounds, process for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1996-11-20 EP claimed
EP-4356894-A1 SUSTAINABLE PRODUCT WITH MALODORS Beiersdorf AG (DE) 2024-04-24 EP disclosed
US-20230174514-A1 AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2023-06-08 US disclosed
EP-3402784-A1 3-((HETERO-)ARYL)-ALKYL-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES Grünenthal GmbH (DE) 2018-11-21 EP disclosed
US-9926319-B2 Pyridyl piperidines MERCK PATENT GMBH (DE) 2018-03-27 US disclosed
WO-2017121648-A1 3-((HETERO-)ARYL)-ALKYL-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES Grünenthal GmbH (DE) 2017-07-20 WO disclosed
EP-3169665-A1 SUBSTITUTED AZA-SPIRO(4.5)DECAN-DERIVATIVES Grünenthal GmbH (DE) 2017-05-24 EP disclosed
EP-1032560-A1 POSITION-4 SUBSTITUTED 2-PYRROLIDINONE DERIVATIVES TO REDUCE THE LEVEL OF EXTRACELLULAR GLUTAMATE KLINIKUM DER ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) 2000-09-06 EP disclosed
EP-0743312-B1 Spiroheterocyclic compounds, process for their preparation and pharmaceutical compositions containing them ADIR (FR) 1999-11-17 EP disclosed
WO-1999025683-A1 POSITION-4 SUBSTITUTED 2-PYRROLIDINONE DERIVATIVES TO REDUCE THE LEVEL OF EXTRACELLULAR GLUTAMATE KLINIKUM DER ALBERT-LUDWIGS-UNIVERSITäT FREIBURG (DE) 1999-05-27 WO disclosed
US-5849802-A Fungicidal spirocyclic amines AMERICAN CYANAMID COMPANY (US) 1998-12-15 US disclosed
EP-0743312-A1 Spiroheterocyclic compounds, process for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1996-11-20 EP disclosed
EP-0418190-A2 Use of 1-oxaspiro[4.4]nonan-2-on as a perfuming agent Dragoco Gerberding & Co. GmbH (DE) 1991-03-20 EP disclosed
EP-0414275-A2 Process for the preparation of cyclic aminoacid derivitives as well as the intermediate products GÖDECKE AKTIENGESELLSCHAFT (DE) 1991-02-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210380606-A1 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS ADORA2A, ADORA2B, ADORA1 TRIM24 4135/4885TRIM33 2730/4885ALDH1A1 343/4885
US-20230174514-A1 AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS CCR6, CCR1, CCR3 TRIM24 1099/4885TRIM33 1051/4885ALDH1A1 1097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.